• TG Therapeutics recently reported past second-quarter 2026 results showing revenue of US$240.34 million versus US$141.15 million a year earlier, while net income decreased to US$7.78 million from US$28.19 million.
• Alongside this mixed profitability picture, the company raised its full-year 2026 total global revenue outlook to approximately US$950 million, highlighting management’s confidence in its commercial trajectory.
• We’ll now assess how stronger revenue trends and higher full-year guidance reshape TG Therapeutics’ existing investment narrative and risk profile.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe BRIUMVI can keep growing as the core MS franchise while the pipeline gradually broadens that base. The latest results reinforce the revenue side of that story but highlight how profitability can fluctuate, which keeps pricing pressure and reimbursement risk front and center as the key near term concern. The higher 2026 revenue outlook is encouraging, yet it does not remove TG’s single-product and payer-exposure risks.

The most relevant update here is the company’s decision on 3 August 2026 to lift full year 2026 total global revenue guidance to about US$950 million. That higher target sits alongside the strong first half revenue run rate and links directly to the main catalyst investors are watching: whether commercial execution on BRIUMVI can support management’s more ambitious top line goals without further squeezing margins.

Yet beneath this stronger revenue guidance, investors should still be aware of how payer pushback on high cost MS drugs could...

TG Therapeutics’ narrative projects $1.7 billion revenue and $616.2 million earnings by 2029.

Uncover how TG Therapeutics' forecasts yield a $51.71 fair value, a 6% upside to its current price.

Exploring Other Perspectives

The most bullish analysts already expected revenue to reach about US$2.0 billion and earnings near US$687.2 million by 2029, so this quarter’s guidance boost will likely prompt some to revisit just how quickly subcutaneous BRIUMVI could scale or how much pricing pressure might temper that growth.

Explore 6 other fair value estimates on TG Therapeutics - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.